KLK3 and prostate cancer: In an ancillary study of the NRG/RTOG 9601 trial, Decipher was validated and independently associated with distant metastases (hazard ratio [HR] 1.17, 95% CI 1.05-1.32, p=0.006), prostate cancer-specific mortality (HR 1.39, 95% CI 1.20-1.63, p<0.001), and overall survival (HR 1.17, 95%CI 1.06-1.29, p=0.002), after adjusting for age, race/ethnicity, Gleason score, T stage, margin status, entry PSA, and treatment arm (45).